Drug intelligence / Profile preview

Canthex

Development stage: Preclinical
Lead developer: Torrent Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Canthex is an oral **nutraceutical fixed-dose combination** marketed in India for darkened skin patches in flexural areas, including the neck, axillae, and knuckles, and has been studied in acanthosis nigricans. The current Torrent Pharmaceuticals capsule formulation contains alpha-lipoic acid, biotin, chromium polynicotinate, and zinc sulfate monohydrate. Alpha-lipoic acid provides antioxidant and metabolic cofactor activity, while biotin, chromium, and zinc provide micronutrient support relevant to cellular metabolism, glucose handling, and skin health. A historical Canthex formulation studied in a randomized trial contained calcium pantothenate instead of chromium polynicotinate.

Brand names: Canthex

Targets

PCC (Propionyl-CoA carboxylase)

Beyond the preview

Go deeper on Canthex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canthex.

Explore the full profile